Health Canada has approved Rymti, its biosimilar to Enbrel (etanercept), for use in Canada, a statement from Lupin has notified.
According to the statement, Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
Nice and helpful information shared. . Good Work. keep it up.